Supernus Pharmaceuticals (NASDAQ:SUPN) Now Covered by Cantor Fitzgerald

Research analysts at Cantor Fitzgerald started coverage on shares of Supernus Pharmaceuticals (NASDAQ:SUPN) in a report issued on Monday,Briefing.com Automated Import reports. The brokerage set an “overweight” rating and a $57.00 price target on the specialty pharmaceutical company’s stock. Cantor Fitzgerald’s price objective suggests a potential upside of 54.39% from the company’s current price.

A number of other equities analysts have also commented on SUPN. Piper Sandler reissued a “neutral” rating on shares of Supernus Pharmaceuticals in a research report on Friday, October 18th. Cowen reiterated a “buy” rating on shares of Supernus Pharmaceuticals in a report on Friday, October 18th.

Supernus Pharmaceuticals Stock Up 1.3 %

NASDAQ SUPN opened at $36.92 on Monday. The company has a 50 day moving average price of $36.16 and a two-hundred day moving average price of $32.97. Supernus Pharmaceuticals has a 12-month low of $25.53 and a 12-month high of $39.37. The stock has a market capitalization of $2.04 billion, a PE ratio of 34.50 and a beta of 0.90.

Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its earnings results on Monday, November 4th. The specialty pharmaceutical company reported $0.69 EPS for the quarter, topping the consensus estimate of $0.44 by $0.25. Supernus Pharmaceuticals had a net margin of 9.16% and a return on equity of 7.79%. The firm had revenue of $175.70 million for the quarter, compared to the consensus estimate of $157.35 million. During the same period in the prior year, the business posted ($0.29) earnings per share. The business’s quarterly revenue was up 14.2% on a year-over-year basis. As a group, equities analysts anticipate that Supernus Pharmaceuticals will post 2.37 EPS for the current year.

Insider Activity

In related news, CEO Jack A. Khattar sold 125,000 shares of the stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $36.68, for a total value of $4,585,000.00. Following the completion of the sale, the chief executive officer now owns 926,172 shares in the company, valued at approximately $33,971,988.96. This trade represents a 11.89 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Georges Gemayel sold 14,213 shares of Supernus Pharmaceuticals stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $36.62, for a total value of $520,480.06. Following the sale, the director now directly owns 13,315 shares in the company, valued at approximately $487,595.30. This trade represents a 51.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 154,213 shares of company stock valued at $5,660,180. 9.30% of the stock is owned by company insiders.

Hedge Funds Weigh In On Supernus Pharmaceuticals

Several institutional investors have recently bought and sold shares of the business. JPMorgan Chase & Co. lifted its holdings in Supernus Pharmaceuticals by 40.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 253,396 shares of the specialty pharmaceutical company’s stock worth $7,901,000 after buying an additional 73,118 shares in the last quarter. Principal Financial Group Inc. lifted its stake in shares of Supernus Pharmaceuticals by 5.4% during the third quarter. Principal Financial Group Inc. now owns 285,411 shares of the specialty pharmaceutical company’s stock valued at $8,899,000 after acquiring an additional 14,566 shares during the period. Franklin Resources Inc. lifted its stake in shares of Supernus Pharmaceuticals by 7.6% during the third quarter. Franklin Resources Inc. now owns 29,981 shares of the specialty pharmaceutical company’s stock valued at $987,000 after acquiring an additional 2,121 shares during the period. Geode Capital Management LLC boosted its holdings in Supernus Pharmaceuticals by 5.3% in the third quarter. Geode Capital Management LLC now owns 1,482,051 shares of the specialty pharmaceutical company’s stock valued at $46,218,000 after acquiring an additional 74,438 shares during the last quarter. Finally, Barclays PLC increased its position in Supernus Pharmaceuticals by 88.3% in the third quarter. Barclays PLC now owns 108,788 shares of the specialty pharmaceutical company’s stock worth $3,393,000 after purchasing an additional 51,005 shares during the period.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.